HOME MAJOR NEEDS SCIENCE PRODUCTS PEOPLE PRESS INVESTORS CAREERS REGION OUR PIPELINE By targeting the GI pathway, Gelesis has the potential to transform how related chronic diseases are treated. TECHNOLOGY PIPELINE POSTERS AND PUBLICATIONS PRESENTATIONS * Products are investigational and have not been cleared by the FDA for use in the United States. Other pre-clinical programs: GS400 for IBD in pre-clinical stage. PLENITY® now FDA Cleared PLENITY® CLINICAL DATA Stay up to date with Gelesis innovations STAY IN TOUCH © 2021 Gelesis – All rights reserved Terms and conditions Privacy Policy E.U. GDPR – English | Italian Social Media Community Guidelines Patent Notice Contact

HOME MAJOR NEEDS SCIENCE PRODUCTS PEOPLE PRESS INVESTORS CAREERS REGION PATENT NOTICE Virtual Patent Marking Notice by Gelesis Inc. The following products are protected by patents in the U.S. and elsewhere for Gelesis Inc. This website is provided to satisfy the virtual patent marking provisions of various jurisdictions including the virtual patent marking provisions of the America Invents Act and to provide notice under 35 U.S.C. §287(a). The following list of products and patents may not be all inclusive. For example, some products listed here may be covered by patents in the United States and elsewhere that are not listed, and other products not listed here may be protected by one or more patents in the United States and elsewhere. The following products may be covered by one or more of the following U.S. Patents: Product Name PLENITY™ Patent Number(s) US 8,658,147; US 9,353,191; Patent Pending © 2021 Gelesis – All rights reserved Terms and conditions Privacy Policy E.U. GDPR – English | Italian Social Media Community Guidelines Patent Notice Contact